A Study of Tirzepatide (LY3298176) in Healthy Participants

What this study is testing ClinicalTrials.gov NCT03375463 ↗

Description as written by the study sponsor.

This study has four parts. Each participant will enroll in one part. Part A: The purpose of Part A is to compare study drug tirzepatide solution formulation to a powder formulation mixed with water and given subcutaneously (SC) (just under the skin). Part A will measure how much of the study drug gets into the blood stream and how long it takes the body to get rid of it. Part B: The purpose of Part B is to evaluate the safety and tolerability of tirzepatide intravenous (IV) formulation when administered into a vein. Part C: The purpose of Part C is to evaluate the safety and tolerability of tirzepatide following multiple SC weekly doses of a solution. Part D: The purpose of Part D is to evaluate the safety and tolerability of tirzepatide following single IV bolus dose of lyophilized formulation. This study will last approximately 70 days for each part (Part A, Part B or Part D) and 92 days for Part C. This does not include screening. Screening is required within 28 days prior to the start of the study.

Treatments tested

• Tirzepatide also known as LY3298176 Drug

  Administered SC

• Tirzepatide also known as LY3298176 Drug

  Administered IV

• Placebo Drug

  Administered SC

• Tirzepatide also known as LY3298176 Drug

  Administered IV